Product Images Lisdexamfetamine Dimesylate

This text is a medication label for Lisdexamfetamine Dimesylate Capsules with NDC 04203565 01. It provides information on the dosage, storage instructions, manufacturer details, and cautions. Each capsule contains Lisdexamfetamine Dimesylate 10 g (equivalent to 5.8 g of dextroamphetamine). The usual dosage information is not available in the text. The medication should be kept in a tight, light-resistant container at temperatures between 15-30°C (59-86°F). The manufacturer is Ten Pharmaceuticals. This text prompts the pharmacist to dispense the accompanying Medication Guide to each patient.*

This text contains information about a medication: NDC 0460-3566.01, which is examfetamine Dimesylate capsules (20mg). It provides instructions for pharmacists to dispense the accompanying Medication Guide to each patient. The medication is from Teva Pharmaceuticals and each capsule contains 20mg of dexmethylphenidate. It also includes cautionary information about storage and dosage. The last part shows codes related to serialization.*

This is a prescription for Lisdexamfetamine Dimesylate capsules, with a prescription for 100 capsules. It is essential for the pharmacist to dispense the medication guide to each patient. Each capsule contains Lisdexamfetamine dimesylate 30mg, equivalent to 10.17 mg of dextroamphetamine. It should be stored at room temperature and kept out of reach of children. The manufacturer is Teva Pharmaceuticals.*

This is a medication label for Lisdexamfetamine Dimesylate capsules with a lot number of 0460-3568-01. The pharmacist should dispense the accompanying Medication Guide to each patient. Each capsule contains a specific dosage of the active ingredient. The storage instructions recommend keeping the capsules at controlled room temperature. The label provides contact information for the manufacturer.*

This is a prescription label for Lisdexamfetamine, also known as Vyvanse. The medication is in capsule form and contains 60 mg. The prescription is advised to be kept out of the reach of children. The pharmacist is instructed to dispense 100 capsules to the patient along with the accompanying Medication Guide.*

This text provides information related to a special population with a focus on Gender (Male/Female), Age (65-74 years), and End Stage Renal Disease. Additionally, it mentions a percentage of 7% and includes data related to fold change and 90% CI (Confidence Interval). The text seems to be part of a research analysis or report.*

This text appears to outline changes in PK (pharmacokinetics) parameters such as Cmax and AUC for the drugs Guanfacine, Venlafaxine, and Omeprazole. It also mentions fold change and 90% confidence interval. The document seems to provide information on these parameters relative to a reference drug or condition.*

This information provides a list of interacting drugs and their respective substrates related to specific cytochrome P450 enzymes (CYP). Additionally, it includes PK information such as fold change and 90% confidence threshold and a change relative to the reference. The text also mentions specific drugs like Guanfacine, Venlafaxine, Caffeine, Dextromethorphan, Omeprazole, and Midazolam.*

This is a table showing the LS Mean (SE) SKAMP Deportment Scores for placebo and Lisdexamfetamine Dimesylate Capsules over time post-dose in hours. The scores range from 20 to 00, with data points at various time intervals from 0 to 75 hours.*

This is a comparison of the proportion of subjects experiencing relapse or treatment failure between a placebo group and a group taking Lisdexamfetamine Dimesylate Capsules over a period of 35 to 40 days after randomization.*

This text seems to be a table showing the proportion of subjects with relapse over time for Lisdexamfetamine Dimesylate Capsules compared to a Placebo. The data includes the number of subjects at risk at different time points after randomization.*